• 1. Aggregation-induced chiroptical generation and photoinduced switching of achiral azobenzene-alt-fluorene copolymer endowed with left- and right-handed helical polysilanes?
  Hailing Chen,Lu Yin,Meng Liu,Laibing Wang,Michiya Fujiki,Wei Zhang RSC Adv., 2019,9, 4849-4856
• 2. Aggregation, pretransitional behavior, and optical properties in the isotropic phase of lyotropic chromonic liquid crystals studied in high magnetic fields
  Tanya Ostapenko,Peter J. Collings,Samuel N. Sprunt,J. T. Gleeson Soft Matter, 2013,9, 9487-9498
• 3. An atomic scale study of defects in Co2FeAl
  Ravi Kumar Yadav,R. Govindaraj Phys. Chem. Chem. Phys., 2020,22, 26876-26886
• 4. An integrated digital microfluidic chip for multiplexed proteomic sample preparation and analysis by MALDI-MS?
  Hyejin Moon,Aaron R. Wheeler,Robin L. Garrell,Chang-Jin “CJ” Kim Lab Chip, 2006,6, 1213-1219
• 5. An insight into the origin of room-temperature ferromagnetism in SnO2 and Mn-doped SnO2 quantum dots: an experimental and DFT approach?
  Dhamodaran Manikandan,S. Amirthapandian,I. S. Zhidkov,A. I. Kukharenko,S. O. Cholakh,Ramaswamy Murugan Phys. Chem. Chem. Phys., 2018,20, 6500-6514

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Azoles Pyrazoles

Recent Advances in the Study of 1-(2-bromoethyl)-4-methyl-1H-pyrazole (CAS: 1023299-43-5) in Chemical Biology and Pharmaceutical Research

1-(2-bromoethyl)-4-methyl-1H-pyrazole (CAS: 1023299-43-5) is a pyrazole derivative that has garnered significant attention in recent years due to its potential applications in medicinal chemistry and drug discovery. This compound serves as a versatile intermediate in the synthesis of biologically active molecules, particularly in the development of kinase inhibitors and other therapeutic agents. Recent studies have explored its reactivity, pharmacological properties, and utility in targeted drug design, making it a compound of interest for researchers in the field.

One of the key areas of research involving 1-(2-bromoethyl)-4-methyl-1H-pyrazole is its role as a building block for the synthesis of kinase inhibitors. Kinases are critical targets in cancer therapy, and the ability to modify the pyrazole core with various substituents allows for the creation of compounds with enhanced selectivity and potency. Recent publications have highlighted its use in the development of novel inhibitors targeting specific kinases, such as JAK2 and CDK4/6, which are implicated in various malignancies.

In addition to its applications in kinase inhibitor development, 1-(2-bromoethyl)-4-methyl-1H-pyrazole has been investigated for its potential in other therapeutic areas. For example, researchers have explored its incorporation into small molecules designed to modulate GPCRs (G-protein-coupled receptors) and ion channels, which are important targets for neurological and cardiovascular diseases. The bromoethyl moiety of the compound provides a handle for further functionalization, enabling the attachment of diverse pharmacophores to optimize drug-like properties.

Recent synthetic methodologies have also focused on improving the efficiency and scalability of producing 1-(2-bromoethyl)-4-methyl-1H-pyrazole. Advances in catalysis and green chemistry have led to more sustainable routes for its synthesis, reducing the environmental impact and cost associated with large-scale production. These developments are particularly relevant for pharmaceutical companies looking to incorporate this intermediate into their drug discovery pipelines.

Despite its promising applications, challenges remain in the use of 1-(2-bromoethyl)-4-methyl-1H-pyrazole. Issues such as stability under physiological conditions and potential off-target effects need to be addressed through further research. However, ongoing studies are leveraging computational modeling and high-throughput screening to optimize its derivatives for improved pharmacokinetic and safety profiles.

In conclusion, 1-(2-bromoethyl)-4-methyl-1H-pyrazole (CAS: 1023299-43-5) represents a valuable tool in the toolkit of medicinal chemists. Its versatility and potential for modification make it a key intermediate in the development of next-generation therapeutics. As research continues to uncover new applications and refine synthetic approaches, this compound is poised to play an increasingly important role in chemical biology and pharmaceutical innovation.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)